Longevity eye cream
US-2024423898-A1 · Dec 26, 2024 · US
US2016331698A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016331698-A1 |
| Application number | US-201515111331-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jan 13, 2015 |
| Priority date | Jan 13, 2014 |
| Publication date | Nov 17, 2016 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed herein are small-gap fullerene compositions and methods of using for therapeutic or cosmetic purposes. Specifically exemplified is the use of derivatized SGFs so as to be water-soluble. The derivatized SGFs include polyhydroxylated and polycarboxylated SGFs.
Opening claim text (preview).
What is claimed is: 1 . A method of treating or preventing an unwanted condition, disease or symptom of a patient associated with oxidative stress comprising administering a therapeutically effective amount or prophylactically effective amount of a small-gap fullerene (SGF) composition to a subject in need. 2 . The method of claim 1 , wherein said SGF composition comprises SGF compounds ranging from a size of C 60 to C 400 . 3 . The method of claim 1 , wherein the SGF composition comprises SGFs with at least fifty percent being water-soluble SGFs. 4 . The method of claim 3 , wherein the water-soluble SGFs comprise polyhydroxylate SGFs (PSGFs) or polycarboxylated SGFs. 5 . The method of claim 2 , wherein said SGF composition comprises a peak distribution of SGF compounds of a size between about C 100 to C 200 . 6 . The method of claim 5 , wherein said peak distribution comprises SGF compounds of a size of about C 120 . 7 . The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier. 8 . The method of claim 1 , wherein the oxidative stress is associated with Abeta. 9 . The method of claim 1 , wherein the unwanted condition is a neurodegenerative disease. 10 . The method of claim 9 , wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, or Dementia with Lewy Bodies. 11 . A method for improving the general condition and appearance of skin, the method comprising administering a cosmetically effective amount of a SGF composition to a patient for cosmetic purposes. 12 . The method of claim 11 , wherein said SGF composition is administered topically. 13 . The method of claim 11 , wherein said method diminishes the appearance of wrinkles. 14 . The method of claim 11 , wherein said SGF composition comprises SGF compounds ranging from a size of C 60 to C 400 . 15 . The method of claim 11 , wherein the SGF composition comprises SGFs with at least fifty percent being water-soluble SGFs. 16 . The method of claim 15 , wherein the water-soluble SGFs comprise polyhydroxylate SGFs (PSGFs) or polycarboxylated SGFs. 17 . The method of claim 11 , wherein said SGF composition comprises a peak distribution of SGF compounds of a size between about C 100 to C 200 . 18 . A composition formulated for topical administration, said composition comprising SGFs and cosmetically acceptable carrier. 19 . The composition of claim 18 , further comprising at least one conjunctive agent. 20 . The composition of claim 19 , wherein said conjunctive agent comprises sun blocking agents, acute or chronic moisturizing agents, anti-oxidants, sunscreens having UVA and/or UVB protection, emollients, anti-irritants, vitamins, trace metals, anti-microbial agents, botanical extracts, fragrances, dyes and color ingredients, structuring agents, and/or emulsifiers 21 . The composition of claim 18 , wherein SGFs comprises at least 50 percent PSGFs.
Free radical scavengers or antioxidants · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Anti-Parkinson drugs · CPC title
Drugs for disorders of the nervous system · CPC title
Emollients or protectives, e.g. against radiation · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.